Clinical Trials Browser

Phase 1 × HR+/HER2- Advanced Breast Cancer × 90 days × Clear all

NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Phase 1 Completed

HR+/HER2- Advanced Breast Cancer